Streetbeat News

Products Services

ABBV

AbbVie announced that its Phase 2 EMPOWER trials for emraclidine in treating schizophrenia did not meet their primary endpoint. The trials failed to show a significant improvement in symptoms compared to placebo, although the drug was well-tolerated.

Portfolio Pulse from

November 11, 2024 | 1:45 pm

AAAU

The article provides an analysis of the gold market for November 11, focusing on key intra-day price entry levels for active traders. Jim Wyckoff, with over 25 years of experience in financial markets, offers insights into the commodity futures trading floors in Chicago and New York.

Portfolio Pulse from

November 11, 2024 | 1:45 pm

NTLA

Intellia Therapeutics' Q3 earnings report highlighted underwhelming Phase II results for NTLA-2002, but management reassured investors, leading to a modest rally. The company plans to start 3 Phase III trials by year-end, offering potential upside. Intellia has a strong financial position with $945 million in cash.

Portfolio Pulse from

November 11, 2024 | 1:45 pm

BDMD

Baird Medical (NASDAQ: BDMD) showcased its microwave ablation technology at the Massachusetts Society of Otolaryngology event, highlighting the trend towards office-based surgical procedures.

Portfolio Pulse from

November 11, 2024 | 1:30 pm

NET

Cloudflare's Q3 FY24 earnings report shows strong growth, with a 28% YoY revenue increase and 49% YoY non-GAAP income growth. The company is focusing on product innovation and sales capacity to reach its $5 billion revenue target, despite a decline in Net Dollar Retention.

Portfolio Pulse from

November 11, 2024 | 1:30 pm

CERO

CERo Therapeutics Holdings, Inc. presented promising preclinical data for its lead compound CER-1236, showing its ability to kill ovarian cancer cells without toxicity. This was announced at the SITC 2024 Conference.

Portfolio Pulse from

November 11, 2024 | 1:30 pm

CNRIF

Condor Resources Inc. has expanded its Huiñac Punta silver prospect in Peru from 2,000 to 7,200 hectares by securing additional exploration concessions. This expansion targets high-grade silver-dominant carbonate replacement-style mineralization.

Portfolio Pulse from

November 11, 2024 | 1:30 pm

SKX

Skechers has seen a 26% increase in its stock price over the past year, driven by strategic infrastructure investments, global expansion, and strong performance in both wholesale and direct-to-consumer segments.

Portfolio Pulse from

November 11, 2024 | 1:30 pm

APVO

Aptevo Therapeutics and Alligator Bioscience announced that their bispecific antibody, ALG.APV-527, met key endpoints in a Phase 1 trial for solid tumors, showing safety, tolerability, and biological activity. The trial results were presented at the Society for Immunotherapy of Cancer.

Portfolio Pulse from

November 11, 2024 | 1:30 pm

SERVE

Serve Robotics is acquiring Vebu, known for the Autocado, to revolutionize kitchen automation in the QSR industry. This move aims to drive significant revenue and improve restaurant productivity, potentially boosting Serve's stock due to increased demand for innovative robotics.

Portfolio Pulse from

November 11, 2024 | 1:30 pm